Jazz Pharmaceuticals plc completed a private offering of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, including the full exercise of the initial purchasers' option to purchase an additional $150 million. Net proceeds are estimated at approximately $1,226.4 million for general corporate purposes. Concurrently, the company repurchased approximately $225.0 million of its ordinary shares from note purchasers at a price of $249.29 per share using existing cash on hand, reducing the remaining authorization under its July 2024 buyback program. The notes mature on September 15, 2032, with semi-annual interest payments beginning March 15, 2027, and an initial exchange rate of 2.8150 ordinary shares per $1,000 principal amount. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing treatments for rare diseases.
